- Pre-existing chronic pulmonary disease - Former diagnosis of Interstitial pulmonary disease - Former diagnosis of COPD 4 or FEV1<30%pred - Previous DLCO <45% - Total lung capacity (TLC) < 60% of predicted - Lung cancer with non-surgical treatment in last year - Chronic home oxygen treatment - Pre-existing heart failure with a known left ventricular ejection fraction <40% - Active treatment of hematological or non-hematological cancer with targeted, immuno- or chemotherapy or targeted radiotherpay in the last year - Inability to provide informed consent - Any subject who had received any investigational medication within 1 month prior to the start of this study or who is scheduled to receive another investigational drug during the course of this study - Active liver disease, porphyria or elevations of serums transaminases >5 x ULN (upper limit of normal) or bilirubin > 1.5 x ULN - History or suspicion of inability to cooperate adequately. - White blood count < 4.0^109/l - Hemoglobin < 6.0 mmol/l - Thrombocytes < 100^109/l - Pregnant female subjects - Breastfeeding female subjects - Use of strong Cyp3A4 inductors, including the following drugs: Carbamazepine, efavirenz, enzalutamide, fenobarbital, fenytoine, hypericum, mitotaan, nevirapine, primidon, rifabutine, rifampicine - Concomittant use of chloroquine or hydroxychloroquine. - QTc >500msec at baseline.

- Pre-existing chronic pulmonary disease - Former diagnosis of Interstitial pulmonary disease - Former diagnosis of COPD 4 or FEV1<30%pred - Previous DLCO <45% - Total lung capacity (TLC) < 60% of predicted - Lung cancer with non-surgical treatment in last year - Chronic home oxygen treatment - Pre-existing heart failure with a known left ventricular ejection fraction <40% - Active treatment of hematological or non-hematological cancer with targeted, immuno- or chemotherapy or targeted radiotherpay in the last year - Inability to provide informed consent - Any subject who had received any investigational medication within 1 month prior to the start of this study or who is scheduled to receive another investigational drug during the course of this study - Active liver disease, porphyria or elevations of serums transaminases >5 x ULN (upper limit of normal) or bilirubin > 1.5 x ULN - History or suspicion of inability to cooperate adequately. - White blood count < 4.0^109/l - Hemoglobin < 6.0 mmol/l - Thrombocytes < 100^109/l - Pregnant female subjects - Breastfeeding female subjects - Use of strong Cyp3A4 inductors, including the following drugs: Carbamazepine, efavirenz, enzalutamide, fenobarbital, fenytoine, hypericum, mitotaan, nevirapine, primidon, rifabutine, rifampicine - Concomittant use of chloroquine or hydroxychloroquine. - QTc >500msec at baseline.

- Pre-existing chronic pulmonary disease - Former diagnosis of Interstitial pulmonary disease - Former diagnosis of COPD 4 or FEV1<30%pred - Previous DLCO <45% - Total lung capacity (TLC) < 60% of predicted - Lung cancer with non-surgical treatment in last year - Home oxygen treatment - Active treatment of hematological or non-hematological cancer with targeted, immuno- or chemotherapy in the last year - Chronic or acute renal failure, defined as eGFR <30ml/min - Inability to provide informed consent - Any subject who had received any investigational medication within 1 month prior to the start of this study or who is scheduled to receive another investigational drug during the course of this study - Active liver disease, porphyria or elevations of serums transaminases >3 x ULN (upper limit of normal) or bilirubin > 1.5 x ULN - History or suspicion of inability to cooperate adequately. - White blood count < 4.0^109/l - Hemoglobin < 6.0 mmol/l - Thrombocytes < 100^109/l - Pregnant female subjects - Breastfeeding female subjects

- Pre-existing chronic pulmonary disease - Former diagnosis of Interstitial pulmonary disease - Former diagnosis of COPD 4 or FEV1<30%pred - Previous DLCO <45% - Total lung capacity (TLC) < 60% of predicted - Lung cancer with non-surgical treatment in last year - Home oxygen treatment - Active treatment of hematological or non-hematological cancer with targeted, immuno- or chemotherapy in the last year - Chronic or acute renal failure, defined as eGFR <30ml/min - Inability to provide informed consent - Any subject who had received any investigational medication within 1 month prior to the start of this study or who is scheduled to receive another investigational drug during the course of this study - Active liver disease, porphyria or elevations of serums transaminases >3 x ULN (upper limit of normal) or bilirubin > 1.5 x ULN - History or suspicion of inability to cooperate adequately. - White blood count < 4.0^109/l - Hemoglobin < 6.0 mmol/l - Thrombocytes < 100^109/l - Pregnant female subjects - Breastfeeding female subjects